‘77.8% is high success rate’: LNJP Director on COVAXIN’s efficacy in phase 3 trials

New Delhi, July 03 (ANI): Lok Nayak Jai Prakash Narayan (LNJP) Hospital Medical Director Dr Suresh Kumar expressed confidence on Bharat Biotech’s COVID vaccine’s (COVAXIN) efficacy rate in phase 3 of clinical trials. “It’s a very good result of the efficiency data of phase 3 clinical trial. 77.8 per cent is very high success rate and again it is a world class vaccine. We welcome these results,” said Dr Suresh Kumar.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting